Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Anaemia
Different MF manifestations may develop and may worsen over time1
of patients with MF are anaemic at diagnosis2*
Most patients with MF will become anaemic over time3
*Based on a cohort of 200 adult patients with MF enrolled in the REALISM UK study, which was a multicentre, retrospective, noninterventional study from 15 National Health Service hospitals across the United Kingdom.2
All the different manifestations of MF can negatively impact a patient’s quality of life1,3-8
Safety info:
Contraindications:
- Hypersensitivity to the active substance or to any of the excipients.
- Pregnancy and breast-feeding.
Undesirable side effects:
Very common: Thrombocytopenia, dizziness, headache, cough, diarrhoea, abdominal pain, nausea, asthenia and fatigue.
Common: Urinary tract infection, upper respiratory tract infection, pneumonia, nasopharyngitis, COVID- 19, cystitis, bronchitis, oral herpes, sinusitis, herpes zoster, cellulitis, respiratory tract infection, sepsis, lower respiratory tract infection, oral candidiasis, skin infection, gastroenteritis, neutropenia, vitamin B1 deficiency, syncope, peripheral neuropathy, paraesthesia, blurred vision, vertigo, hypotension, haematoma, flushing, vomiting, constipation, arthralgia, pain in extremity, pyrexia, alanine transaminase(ALT) increased, aspartate transaminase (AST) increased and contusion.
INDICATION
▼OMJJARA is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
Abbreviations
MF=myelofibrosis.
References
- Mughal Tl, et al. Int J Gen Med. 2014;7:89-101.
- Mead AJ, et al. Ther Adv Hematol. 2022;13:1-15.
- Naymagon L, et al. HemaSphere. 2017;1(1):e1.
- Mesa R, et al. Leuk Res. 2009;33(9):1199-1203.
- Randhawa J, et al. J Hematol Oncol. 2012;5:43.
- Scotch A, et al. Leuk Res. 2017;63:34-40.
- Mesa R, et al. BMC Cancer. 2016;16:167.
- Yu J, et al. Ann Hematol. 2019;98(5):1119-1125.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
Gulf.ProductQualityComplaints@gsk.com
Department of Pharmacovigilance & Drug Information |
دائرة التيقظ و المعلومات الدوائية مركز سلامة الدواء وزارة الصحة, سلطنة عمان هاتف: 0096822357687 / 0096822357690 0096822358489 :فاكس pharma-vigil@moh.gov.om :البريد االكتروني https://moh.gov.om/en/ : الموقع االكتروني |
Trademarks are owned by or licensed to the GSK group of companies
PM-RCH-MML-WCNT-250001 | Date of preparation: September 2025
